97 related articles for article (PubMed ID: 36456)
21. Locomotor stimulation by L-dopa: relative importance of noradrenaline receptor activation.
Andén NE; Strömbom U; Svensson TH
Psychopharmacology (Berl); 1977 Nov; 54(3):243-8. PubMed ID: 413140
[TBL] [Abstract][Full Text] [Related]
22. Dopaminergic metabolism in various rat brain areas after L-dopa loading.
el Gemayel G; Trouvin JH; Prioux-Guyonneau M; Jacquot C; Cohen Y
J Pharm Pharmacol; 1986 Sep; 38(9):691-4. PubMed ID: 2877071
[TBL] [Abstract][Full Text] [Related]
23. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Napolitano A; Zürcher G; Da Prada M
Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
[TBL] [Abstract][Full Text] [Related]
24. Modification of the L-DOPA reversal of reserpine akinesia by inhibitors of dopamine-beta-hydroxylase.
Dolphin A; Jenner P; Marsden CD
Eur J Pharmacol; 1976 Jan; 35(1):135-44. PubMed ID: 1253815
[TBL] [Abstract][Full Text] [Related]
25. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Rose S; Jenner P; Marsden CD
Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
[TBL] [Abstract][Full Text] [Related]
26. Effects of dietary tyrosine on L-dopa- and amphetamine-induced changes in locomotor activity and neurochemistry in mice.
Thurmond JB; Freeman GB; Soblosky JS; Ieni JR; Brown JW
Pharmacol Biochem Behav; 1990 Oct; 37(2):259-66. PubMed ID: 2080188
[TBL] [Abstract][Full Text] [Related]
27. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.
Carey RJ
Brain Res; 1991 Dec; 568(1-2):205-14. PubMed ID: 1814568
[TBL] [Abstract][Full Text] [Related]
28. Proceedings: Biochemical evidence for the involvement of noradrenaline in motor activity produced by L-DOPA in rodents.
Dolphin A; Jenner P; Marsden CD
Br J Pharmacol; 1975 Oct; 55(2):292P. PubMed ID: 1201420
[No Abstract] [Full Text] [Related]
29. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
30. Relationship between the effects of dexamphetamine on locomotion and on striatal [3H]GBR 12783 binding in vivo.
Vaugeois JM; Bonnet JJ; Costentin J
Eur J Pharmacol; 1990 Mar; 178(2):221-7. PubMed ID: 2328762
[TBL] [Abstract][Full Text] [Related]
31. Effects of drug-induced changes in brain monoamines on aggression and motor behavior in mice.
Kramarcy NR; Brown JW; Thurmond JB
Eur J Pharmacol; 1984 Mar; 99(2-3):141-51. PubMed ID: 6203764
[TBL] [Abstract][Full Text] [Related]
32. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
Lee J; Di Marzo V; Brotchie JM
Neuropharmacology; 2006 Sep; 51(3):557-65. PubMed ID: 16806299
[TBL] [Abstract][Full Text] [Related]
33. Effect of stress and L-DOPA administration on mouse striatal tyramine and homovanillic acid levels.
Juorio AV
Brain Res; 1979 Dec; 179(1):186-9. PubMed ID: 509231
[No Abstract] [Full Text] [Related]
34. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
35. Different effects of harmine on plasma concentrations of L-dopa and on cerebral dopamine metabolism in rabbits and rats.
Meneguz A; Betto P; Ricciarello G
Pharmacology; 1994 Jun; 48(6):360-6. PubMed ID: 8047555
[TBL] [Abstract][Full Text] [Related]
36. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
37. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
38. An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Archer T; Fredriksson A
J Neural Transm (Vienna); 2003 Feb; 110(2):183-200. PubMed ID: 12589577
[TBL] [Abstract][Full Text] [Related]
39. Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Serra PA; Esposito G; Enrico P; Mura MA; Migheli R; Delogu MR; Miele M; Desole MS; Grella G; Miele E
Br J Pharmacol; 2000 Jun; 130(4):937-45. PubMed ID: 10864903
[TBL] [Abstract][Full Text] [Related]
40. Normalization of brain serotonin by L-tryptophan in levodopa-treated rats.
Fahn S; Snider S; Prasad AL; Lane E; Makadon H
Neurology; 1975 Sep; 25(9):861-5. PubMed ID: 1172210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
